



## JEA BizDev Consulting Advises NovaRock Biotherapeutics on Partnership with LigaChem Biosciences

CLIENT SHOWCASE September 2, 2025

<u>JEA BizDev Consulting, LLC</u> advised NovaRock Biotherapeutics, Inc., on two out-licensing agreements with LigaChem Biosciences for novel antibodies. Under the agreements, NovaRock granted LigaChem exclusive worldwide rights to develop and commercialize antibody drug conjugates (ADC) incorporating these antibodies.

JEA BizDev Consulting served as transaction advisor to NovaRock Biotherapeutics on this strategic partnership. Financial terms of the license agreements were not disclosed.

The JEA BizDev Consulting team was led by John Adamou, President and Managing Director.

For more information, please refer to the <u>news release</u>.